Streetbeat News

Price Targets

MDT

Evercore ISI Group has maintained an 'Outperform' rating on Medtronic and raised its price target from $100 to $104, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:43 pm

ISRG

Evercore ISI Group has maintained an 'In-Line' rating for Intuitive Surgical (NASDAQ:ISRG) while raising the price target from $410 to $475.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:41 pm

HOLX

Evercore ISI Group analyst Vijay Kumar maintains an In-Line rating on Hologic (NASDAQ:HOLX) and raises the price target from $78 to $82.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:34 pm

GEHC

Evercore ISI Group has maintained an 'Outperform' rating on GE HealthCare Techs and raised its price target from $98 to $102, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:33 pm

EXAS

Evercore ISI Group has maintained an Outperform rating on Exact Sciences and raised the price target from $72 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:31 pm

EW

Evercore ISI Group has maintained an In-Line rating on Edwards Lifesciences but lowered the price target from $76 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:30 pm

NVRO

Citigroup analyst Joanne Wuensch maintains a Neutral rating on Nevro (NYSE:NVRO) and lowers the price target from $6.89 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:28 pm

ENOV

Evercore ISI Group has maintained an 'Outperform' rating on Enovis (NYSE:ENOV) but has lowered the price target from $62 to $58.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:28 pm

MDT

Citigroup analyst Joanne Wuensch maintains a Neutral rating on Medtronic (NYSE:MDT) but raises the price target from $85 to $92.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:27 pm

IART

Citigroup analyst Joanne Wuensch maintains a Sell rating on Integra Lifesciences and lowers the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 4:25 pm